Stablepharma’s Fridge-Free Vaccine that Eliminates the Need for Cold Chain entering First-in-Human UK Clinical Trial. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Stablepharma to begin a Phase I clinical trial with SPVX02, an adult booster vaccine aimed at preventing tetanus and diphtheria (Td) infections. This approval marks a major […]
Read More
London, 19th February 2025 – UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant recognises the company’s cutting-edge fridge-free pharmaceutical technology, which meets EIC’s rigorous criteria for excellence, impact, and risk management. Stablepharma is among 71 companies from 16 countries across Europe selected […]
Read More
Bath, United Kingdom, December 4th, 2024 – Stablepharma Ltd today announces it was named a Fierce Life Sciences Innovation Awards winner by Fierce Biotech and Fierce Pharma in the Biotech Innovation category. The awards program highlights and showcases outstanding innovation that is driving improvements and transforming the industry. “The Innovation Awards winners showcase the organizations that have […]
Read More
Dr. Steven Chatfield appointed as Non-Executive Chairman of Stablepharma, following an extensive career in vaccine R&D and Covid19 Pandemic. Dr. Chatfield, who currently serves on Stablepharma’s Advisory Board, is taking on the role of Non-Executive Chairman of the company in November. He has been instrumental in advising and advancing the launch of SPVX02, a fridge-free […]
Read More
Stablepharma considers IPO, Series B round to bring vaccines to market – CEO 08:00 CEST, 5 April 2023 Stablepharma, a UK developer of the world’s first fridge-free vaccines, is evaluating an IPO and a financing round to bring two vaccines to market, CEO Özgür Tuncer told Mergermarket. The business will take a decision after the summer […]
Read More